$0.1542
-0.0116-7%
Theriva Biologics Inc
TOVXAMEX
Theriva Biologics fell 39.9% from $0.28 to $0.17, behind the S&P 500's +9.8%. Its worst day was Dec 3 (−25.9%), and its low came Nov 9 at $0.17.
Nov 11, 2025 – Nov 9, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-0.45 missed the $-0.38 estimate on $0.00 revenue.
+8.0% · S&P 500 +0.1%
Theriva Biologics shares fell 25.9%, while the S&P 500 rose 0.1%.
Story events cover the past 12 months · Times ET
−25.9%, the year's worst day · S&P 500 +0.1%
Theriva Biologics shares rose 22.6%, while the S&P 500 rose 0.2%.
+22.6% · S&P 500 +0.2%
EPS of $-0.12 beat the $-0.37 estimate on $0.00 revenue.
+1.2% · S&P 500 −1.5%
Theriva Biologics shares rose 19.0%, while the S&P 500 rose 2.5%.
+19.0% · S&P 500 +2.5%
Theriva Biologics closed at its highest level of the year, 48.7% above where the year started.
+59.4%, the year's best day, on 649M shares, the year's heaviest volume · S&P 500 −0.2%
EPS of $-0.05 beat the $-0.05 estimate on $300,000.00 revenue.
+0.5% · S&P 500 +1.4%
– Prolonged overall survival (OS) was observed in heavily pre-treated refractory Head & Neck Squamous Cell Carcinoma (HNSCC) patients administered IV VCN-01 prior to the immune checkpoint inhibitor durvalumab ––
+26.1% · S&P 500 +1.7%
EPS of $-0.07 missed the $-0.05 estimate on $0.00 revenue.
−0.4% · S&P 500 −0.3%
Where it ended: a close of $0.17 on Nov 9, 2026.
Nothing in the past 12 months.
All TOVX dividend historyChart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for TOVX and SPY from Benzinga historical bars. Not investment advice.
